Following the ban on rosiglitazone in Europe, the Indian government has imposed a ban on the import and manufacture of the diabetes drug

An Expert Committee on October 7 recommended a similar ban in India which was enforced with immediate effect.
The Drugs Controller General of India (DCGI) Dr Surinder Singh revealed that directives have been sent to state drugs controllers in the country regarding the suspension of licenses granted to manufacture for sale and distribution of the drug.
Source-